 |
|
 |
New
studies target new markets Originally launched as a niche product for a rare type of haemophilia, NovoSeven® is now a candidate to become the world's first general haemostatic agent. |
| |
Financial
highlights |
| |
Access
to medicines in poor countries |
|
A
new device It is the ambition of Novo Nordisk to launch one new device each year. The latest one the family is innoLet®. |
 |
|
About Perspective
Perspective is published
by Novo Nordisk A/S. Corporate Communications.
It is distributed three times annually to shareholders, press, business
relations, employees and other interested audiences, in two languages.
Circulation: 38.000 Danish and 14.000 English copies. Editor: Peter Haahr. Text: Bryan Wilder, Nich Barfoed and Mike Rulis. Layout and graphic production: Corporate Communications. Printed by: Levison + Johnsen + Johnsen a/s - eco-certified printers. Photo: Jesper Westley ao. Web design: Araneum A/S.
Copyright: The publisher. Reprints of this publication are permissible with due acknowledgement to Novo Nordisk. However, to honour the publisher´s copyright, please inform the publisher of any reprints or copies. Address: Novo Nordisk A/S, Novo Allé, 2880 Bagsværd, Denmark Tel +45 4444 8888. Fax: +45 4444 2314. Email: perspective@novonordisk.com